Skip to main content

Day: January 27, 2022

Tuesday Morning Announces Reporting Date for Second Quarter Fiscal 2022 Results

DALLAS, Jan. 27, 2022 (GLOBE NEWSWIRE) — Tuesday Morning (NASDAQ: TUEM), a leading off-price retailer of home goods and décor, today announced that the Company will hold a conference call to discuss its second quarter fiscal 2022 financial results on Thursday, February 3rd, 2022 at 8:00 am Central Time. A press release detailing the Company’s financial results will be issued before the market opens and prior to the conference call. A live webcast of the conference call will be available in the investor relations section of the Company’s website, www.tuesdaymorning.com. Investors and analysts interested in listening to the call are invited to dial 877-407-9716, or 201-493-6779 if calling internationally, approximately ten minutes prior to the start of the call. A replay of the webcast will be posted on the website for...

Continue reading

Lantronix to Report Fiscal 2022 Second Quarter Results on Feb. 10, 2022

IRVINE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) — Lantronix Inc. (the “Company”) (NASDAQ: LTRX), a global provider of secure turnkey solutions for intelligent IT and Internet of Things (IoT), today announced it will release financial results of its fiscal 2022 second quarter, ended Dec. 31, 2021, on Feb. 10, 2022, after the close of the market. Management will host an investor conference call and audio webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Feb. 10, 2022. To access the live conference call, investors should dial 1-844-802-2442 (US) or 1-412-317-5135 (international) and indicate that they are participating in the Lantronix fiscal 2022 second quarter call. The webcast will be available simultaneously via the investor relations section of the Company’s website at www.lantronix.com.        Investors can access...

Continue reading

Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available for virtual 1X1 meetings with investors registered for the event. About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead...

Continue reading

Tritium Rings Nasdaq Closing Bell in Honor of Listing

Bell Ringing Ceremony Took Place Yesterday at 4:00 pm ET at Nasdaq MarketSite in New York’s Times SquareTritium Ringing Nasdaq Closing BellThe Tritium team rings the Nasdaq closing bell on Australia Day to celebrate the company’s recent listing on the exchange as DCFC.BRISBANE, Australia, Jan. 27, 2022 (GLOBE NEWSWIRE) — Tritium DCFC Limited (“Tritium” or the “Company”) (Nasdaq: DCFC), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today announced that Company management rang the Closing Bell at Nasdaq MarketSite in New York’s Times Square yesterday afternoon at 4:00 p.m. ET, in honor of its listing on the exchange. The Company began trading on Nasdaq on January 14, 2022, following the close of its business combination...

Continue reading

BioAdaptives to Investigate Use of Lung Cleanser for Long-Term Smokers

Company to study OSCPeP device usage for active smokers and second-hand exposure Las Vegas, Nevada, Jan. 27, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioAdaptives, Inc. (OTCMkts:  BDPT) announced today that it is commencing preliminary investigation into the clinical utilization of its Lung Armor™ package, a combination of the Lung Cleanser™ (aka Lung Flute™) device and its PrimiLungs™ all-natural supplement, with respect to the respiratory function of long-time smokers and those exposed to second-hand smoke.  In addition, the Company will be looking for related beneficial effects that can be associated with drinking oxygenated water products made with its recently acquired patented technology. The Lung Cleanser™ is a patented, FDA-cleared, oscillating positive end pressure (OSCPEP) Class II medical device that promotes...

Continue reading

LSI Industries Reports Fiscal Second Quarter 2022 Results and Declares Quarterly Cash Dividend

CINCINNATI, Jan. 27, 2022 (GLOBE NEWSWIRE) — LSI Industries Inc. (NASDAQ: LYTS, “LSI” or the “Company”) a leading U.S. based manufacturer of indoor/outdoor lighting and display solutions, today announced results for the second quarter of fiscal year 2022. FISCAL SECOND QUARTER 2022Total net sales +45% y/y to $111.1 million, organic net sales +19% y/y Lighting sales +27% y/y; Display Solution sales +72% y/y Net Income +41% y/y to $3.1 million, or $0.11 per diluted share Adjusted net income +67% y/y to $4.2 million, or $0.15 per diluted share Adjusted EBITDA +65% y/y to $8.4 millionLSI generated significant year-over-year growth in sales and profitability in the fiscal second quarter, driven by a continued recovery in non-residential construction activity, systemic gains in targeted vertical markets, together with contributions...

Continue reading

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2037. The allowed claims cover a method of treating a patient diagnosed with alcohol use disorder in which the patient also exhibits symptoms of depression with MN-166 (ibudilast). The allowed claims cover a wide range of dosage strengths and dosing regimens of MN-166 (ibudilast). The allowed claims also...

Continue reading

Radisson intersects 38.34 g/t gold over 2.00 m from initial exploration program to the west of the old O’Brien mine

Figure 1Au Grade Distribution: OB-21-186, OB-21-189, OB-21-190, OB-21-192, OB-21-224, OB-21-250, OB-21-254Figure 2O’Brien Gold Project: Resource Block Model @ 5.0 g/t cut-off; Longitudinal section looking NorthFigure 3O’Brien Gold Project: O’Brien west – Longitudinal sectionFigure 4O’Brien Gold Project: O’Brien west – Cross sectionROUYN-NORANDA, Québec, Jan. 27, 2022 (GLOBE NEWSWIRE) — Radisson Mining Resources Inc. (TSX-V: RDS, OTC: RMRDF): (“Radisson” or the “Company”) is pleased to announce significant high-grade gold intercepts from the ongoing 130,000 m exploration drill program at its 100% owned O’Brien gold project located along the Larder-Lake-Cadillac Break (see location map 1 and location map 2), halfway between Rouyn-Noranda and Val-d’Or...

Continue reading

Amalgamated Financial Corp. Reports Fourth Quarter 2021 Financial Results

NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) — Amalgamated Financial Corp. (the “Company” or “Amalgamated”) (Nasdaq: AMAL), the holding company for Amalgamated Bank (the “Bank”), today announced financial results for the fourth quarter ended December 31, 20211. Fourth Quarter 2021 HighlightsNet income of $15.9 million, or $0.50 per diluted share, compared to $14.4 million, or $0.46 per diluted share, for the third quarter of 2021 and $13.8 million, or $0.44 per diluted share for the fourth quarter of 2020. Total assets exceeded $7.0 billion for the first time. Deposits increased $131.8 million to $6.4 billion on a linked quarter basis. Political deposits remained strong and stable at $989.6 million as of December 31, 2021. Cost of deposits was 0.09%, down four basis points from the fourth quarter of 2020. Net loans, not including...

Continue reading

Brunswick Corporation Releases Fourth Quarter & Full Year 2021 Earnings

METTAWA, Ill., Jan. 27, 2022 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) today has released its fourth quarter and full year 2021 financial results. A complete and full-text financial results press release is available on the Company’s website at www.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at https://goo.gl/wJQN1. The Company will hold a conference call today at 10 a.m. CST/ 11 a.m. EST hosted by David M. Foulkes, chief executive officer, Ryan M. Gwillim, executive vice president and chief financial officer and Brent G. Dahl, vice president of investor relations.  The call will be broadcast over the Internet at www.brunswick.com. To listen to the call, go to the website at least 15 minutes before the call to register, download and install any needed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.